All In Biotech

Drug Trial Radar · NCT07674862

Safety, Tolerability and Pharmacokinetics of ETD-001 Gel

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ETD-001 Gel in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Mar 16, 2026

Primary completion

Jul 5, 2026

Study completion Aug 30, 2026

Sponsor

Lead sponsor
Etern Therapeutics Wuxi LimitedAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, which comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in healthy subjects.Three dose groups are pre-scheduled for the SAD part. After the safety and tolerability of subjects in the second SAD dose group are confirmed, the MAD part will be initiated upon evaluation by the Safety Review Committee (SRC). Four dose groups are tentatively planned for the MAD part.Each dose group will enroll 8 subjects, who will be randomized at a 6:2 ratio to receive either ETD-001 gel or placebo.

Conditions

  • Safety Issues

Interventions

  • Dose 1Drug

    low dose

  • dose 2Drug

    middle dose

  • dose 3Drug

    high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ETD-001 in healthy Chinese subjects.Time frame: Up to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.